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Background: Peripheral artery disease causes significant functional disability and results
in impaired quality of life. Ischemic tissue injury releases various endogenous ligands for
Toll-like receptors (TLRs), suggesting the involvement of TLRs in blood flow recovery.
However, the role of TLR9, which was originally known as a sensor for bacterial DNA,
remains unknown. This study investigated the role of TLR9 in blood flow recovery in the
ischemic limb using a mouse hind-limb ischemia model.
Methods and Results: Unilateral femoral artery ligation was performed in
TLR9-deficient (Tlr9−/−) mice and wild-type mice. In wild-type mice, femoral artery
ligation significantly increased mRNA expression of TLR9 in the ischemic limb (P <
0.001) and plasma levels of cell-free DNA (cfDNA) as determined by single-stranded
DNA (ssDNA) (P < 0.05) and double-stranded DNA (dsDNA) (P < 0.01), which
are endogenous ligands for TLR9, compared with the sham-operated group. Laser
Doppler perfusion imaging demonstrated significantly improved ratio of blood flow
in the ischemic to non-ischemic limb in Tlr9−/− mice compared with wild-type
mice at 2 weeks after ligation (P < 0.05). Tlr9−/− mice showed increased capillary
density and reduced macrophage infiltration in ischemic limb. Genetic deletion of
TLR9 reduced the expression of TNF-α, and attenuated NF-κB activation in ischemic
muscle compared with wild-type mice (P < 0.05, respectively) at 3 days after
the surgery. ODN1826, a synthetic agonistic oligonucleotide for TLR9, or plasma
obtained from mice with ischemic muscle promoted the expression of TNF-α in
wild-type macrophages (P < 0.05), but not in Tlr9−/− macrophages. ODN1826 also
activated NF-κB signaling as determined by the degradation of IκBα in wild-type
macrophages (P < 0.05), but not in Tlr9−/− macrophages. In vitro experiments
using human umbilical vein endothelial cells demonstrated that TNF-α, or conditioned
medium obtained from wild-type macrophages treated with ODN1826 accelerated
cell death as determined by MTS assay (P < 0.05 and P < 0.01, respectively).
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Conclusion: Our results suggest that ischemic muscle releases cfDNA, which activates
TLR9 and enhances inflammation, leading to impairment of blood flow recovery in the
ischemic limb. cfDNA-TLR9 signaling may serve as a potential therapeutic target in
ischemic limb disease.
Keywords: hind-limb ischemia, blood flow recovery, Toll-like receptor 9, inflammation, macrophage
INTRODUCTION
Peripheral artery disease (PAD), due to partial or complete
obstruction of the arteries, is one of the most common
manifestations of atherosclerosis, which is associated with
increased risk of cardiovascular events (1). Collateral vessel
development is a physiological response in ischemic tissues
to compensate reduced blood flow. Previous studies indicated
that an inflammatory process regulates neovascularization
and subsequent blood flow recovery (2). In this process, the
immune system plays a pivotal role (3). Exogenous ligands
such as microbial-associated molecules activate macrophages
through Toll-like receptors (TLRs), whereas endogenous
molecules derived from damaged and dead host cells also
activate macrophages though TLRs and promote sterile
inflammation by inducing cytokines (4). Ischemia induces
cellular and tissue damage (5), causing the release of cellular
debris which contains various endogenous ligands for TLRs.
In fact, several studies reported that TLR-2, 3 and 4 participate
in blood flow recovery in ischemic tissues by modulating
inflammation and angiogenesis (6–11). However, the role
of TLR9 in blood flow recovery in ischemic tissues remains
unknown. TLR9 recognizes exogenous DNA fragments which
contain unmethylated CpG-DNA and plays a role in the
innate immune system (12, 13). In addition, accumulating
evidence has revealed that TLR9 has a broad range of functions
in pathophysiological conditions. TLR9 recognizes cell-
free DNA (cfDNA) released from degenerated tissues/cells
and activates inflammatory cells including macrophages,
leading to the development of sterile inflammation-associated
diseases such as autoimmune diseases, insulin resistance, and
others (14–16).
Therefore, in this study, we hypothesized that TLR9
activation by cfDNA released from ischemic tissues promotes
inflammation and modulates blood flow recovery in the
ischemic limb. To test our hypothesis, we induced hind-
limb ischemia in wild-type and TLR9-deficient (Tlr9−/−)
mice and compared blood flow recovery and the degree of
inflammation in the ischemic limb between these strains of
mice. Also, we investigated the role of TLR9 in the link
between inflammation and blood flow recovery in ischemic
tissue.
Abbreviations: cfDNA, cell-free DNA; CM, conditioned medium; dsDNA,
double-stranded DNA; HUVEC, human umbilical vein endothelial cells; PAD,
peripheral artery disease; qPCR, Quantitative real-time RT-PCR; ssDNA, single-
stranded DNA; TLR, Toll-like receptor; Tlr9−/−, TLR9-deficient.
MATERIALS AND METHODS
Animals
C57BL/6 (wild-type) mice and Tlr9−/− mice (C57BL/6
background) were obtained from Japan SLC Inc. and Oriental
BioService, Inc., respectively. Mice were maintained under a
12-h light/dark cycle, with a standard diet and water ad libitum.
All experimental procedures conformed to the guidelines for
animal experimentation of Tokushima University. The protocol
was reviewed and approved by our institutional ethics committee
under No. T29-96.
Hind-Limb Ischemia by Ligation of Femoral
Artery and Blood Flow Monitoring
Unilateral hind-limb ischemia was induced in wild-typemice and
Tlr9−/− mice as described previously (17). Briefly, the animals
were anesthetized by intraperitoneal injection of pentobarbital
(50 mg/kg). The proximal and distal portions of the femoral
artery and the distal portion of the saphenous artery were ligated.
The arteries and all side branches were dissected free and excised.
Blood flow in limbs was measured using a laser Doppler blood
perfusion monitor (Moor LDPI) pre- and post-operatively and
on days 7 and 14. Blood flow recovery in the ischemic limb was
determined by the ratio of perfusion in the ischemic limb to the
untreated limb.
Immunohistochemical Staining
Capillary density in the ischemic limb was measured as
described previously (17). At 14 days after femoral artery
ligation, mice were sacrificed by intraperitoneal injection of
an overdose of pentobarbital. The whole limbs were fixed in
methanol overnight, and the ischemic muscles were embedded
in paraffin. Sections (5µm) were de-paraffinized and incubated
with an anti-CD31 antibody (clone MEC13.1, BD Pharmingen).
Antibody distribution was detected with the avidinbiotin-
complex technique and a Vector Red Alkaline Phosphatase
substrate kit (Vector Laboratories). Nuclei were stained with
hematoxylin. Six different fields from each section were randomly
selected, and visible CD31-positive capillaries were quantitated
with a FLOVEL Filing System (FLOVEL Company, Ltd.).
Capillary density was expressed as the number of capillaries per
field or per muscle fiber.
Accumulation of macrophages in ischemic limb was also
examined by immunohistochemistry. Sections were incubated
with anti-Mac3 antibody (BD Pharmingen). Development was
performed by the combination of HRP-conjugated secondary
antibody and ImmPACT DAB substrate (Vector Laboratories).
Sections were counterstained with hematoxylin. Four different
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fields from each section were randomly selected, and Mac3-
positive cells were quantitated with CellSens (OLYMPUS).
Accumulation of macrophages was determined as the number of
macrophages per field or per muscle fiber.
Cell Culture
Thioglycollate-stimulated peritoneal macrophages were
collected with cold PBS from age-matched female wild-
type mice or Tlr9−/− mice at the age of 8-12 weeks and
cultured in DMEM containing 10% FBS at 37◦C in a
humidified incubator in 5% CO2 and 95% air. At 24 h
after plating, isolated peritoneal macrophages were used for
experiments. Peritoneal macrophages were stimulated with
ODN1826 or control-ODN1826 (GeneDesign, Inc.), synthetic
oligonucleotides that contain unmethylated CpG, for indicated
time. We collected plasma from wild-type mice at 3 days
after femoral artery ligation or sham-operation. Wild-type
or Tlr9−/− macrophages were stimulated with these plasma
for 4 h.
Human umbilical vein endothelial cells (HUVEC)
were purchased from Life Technologies and grown in
EGM-2 (Lonza) at 37◦C in a humidified incubator in 5%
CO2 and 95% air. HUVEC (passages 4-6) were used for
experiments.
Assessment of Cell Viability
HUVEC were plated in 96-well plates and grown to 40∼50%
confluence in EGM-2, and then stimulated with or without
human recombinant TNF-α for 24 h in EBM-2 containing
1% FBS. Cell viability of HUVEC was determined by
MTS assay using a CellTiter 96 AQueous One Solution
Cell Proliferation Assay kit (Promega) according to the
manufacturer’s instructions. The percentage of absorbance was
calculated against that of non-stimulated cells. Cell viability of
HUVEC was also examined after treatment with conditioned
medium (CM) of macrophages. Wild-type macrophages or
Tlr9−/− macrophages were pretreated with ODN1826 or
control-ODN1826 (100 nM) under serum-starved conditions for
24 h, and then cells were cultured for another 24 h in a starvation
medium without synthetic oligonucleotides. CM was collected
after centrifugation and filtration through a 40-µm mesh to
remove cell debris. Cell viability was determined by MTS assay
after 72-h incubation.
Measurement of cfDNA in Plasma
cfDNA in plasma was extracted using a QIAamp DNA Mini
Kit (Qiagen), according to the manufacturer’s instructions. The
concentrations of single-stranded DNA (ssDNA) and double-
stranded DNA (dsDNA) in extracted cfDNA were measured
using a QuantiFluor ssDNA System (Promega) and Quant-iT
PicoGreen dsDNA Assay Kit (Life Technologies), respectively,
according to the instructions.
Reverse Transcription and Quantitative
Real-Time Polymerase Chain Reaction
RNA extracted from muscles and cells with an illustra
RNAspin RNA Isolation Kit (GE Healthcare) was used for
cDNA synthesis using a QuantiTect Reverse Transcription
kit (Qiagen). Quantitative real-time RT-PCR (qPCR) was
performed using Power SYBR Green PCR Master Mix (Applied
Biosystems) and gene-specific primers on an Mx3000P (Agilent
Technologies). Data are expressed in arbitrary units normalized
by β-actin. The sequences of primers used in this study
were as follows: TNF-α, sense 5′-accctcacactcagatcatcttc-3′
and antisense 5′-tggtggtttgctacgacgt-3′; F4/80, sense 5′-tgc
atctagcaatggacagc-3′ and antisense 5′-gccttctggatcCATttgaa-
3′; β-actin, sense 5′-CCTgagcgcaagtactctgtgt-3′ and antisense
5′-gctgatccacatctgctggaa-3′.
Western Blot Analysis
Protein lysates were isolated from tissues or cells using RIPA
buffer (Wako Pure Chemical Industries, Ltd.) containing a
protease inhibitor cocktail (Takara Bio Inc.) and phosphatase
inhibitors (Roche LifeScience). Proteins were separated by SDS-
PAGE and transferred to polyvinilidine difluoride membranes
(Hybond-P; GE Healthcare). The membrane was blocked
in 5% BSA for 1 h at room temperature, followed by
incubation with a primary antibody against either total-
IκBα (Cell Signaling Technology), TNF-α (abcam), α-Tubulin
(MBL), or β-actin (Sigma) at 4◦C overnight. After blots were
washed in TBS containing 1% Tween-20, the membranes
were incubated in horseradish peroxidase-conjugated secondary
antibody (Chemicon) for 1 h. Expression of α-Tubulin or β-actin
was used as an internal control to confirm equivalent total
protein loading. Antibody distribution was visualized with ECL-
plus reagent (GE Healthcare) using a luminescent image analyzer
(LAS-1000, Fuji Film).
Statistical Analysis
Data were expressed as mean± SEM. Comparisons between two
groups were made by unpaired Student’s t test. Comparisons
of multiple groups were made by one-way analysis of variance
(ANOVA) followed by Tukey test. P < 0.05 was considered
statistically significant.
RESULTS
Femoral Artery Ligation Increased
Expression of TLR9 in Ischemic Limb and
Endogenous Ligand for TLR9 in Blood
To determine the participation of TLR9 in blood flow
recovery of the ischemic limb, we examined the expression
of TLR9 and circulating level of TLR9 ligand at 3 days
after femoral artery ligation in wild-type mice. Results of
qPCR demonstrated that ligation of the femoral artery
markedly increased Tlr9 expression in the ischemic limb
compared to the sham operated group (Figure 1A).
Induction of hind-limb ischemia in wild-type mice also
increased the plasma levels of dsDNA and ssDNA, internal
ligands for TLR9, compared with the sham-operated group
(Figures 1B,C).
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FIGURE 1 | Femoral artery ligation increased TLR9 expression in ischemic limb and circulating level of endogenous TLR9 ligand. (A) Femoral artery ligation increased
TLR9 expression in the ischemic limb at 3 days after surgery in wild-type mice (N = 7, per group). (B,C) Induction of ischemia increased plasma circulating level of
cfDNA as determined by dsDNA and ssDNA at 3 days after surgery in wild-type mice (N = 7, ligated group; N = 8, sham operated group). *P < 0.05, **P < 0.01, and
***P < 0.001. All values are mean ± SEM.
TLR9 Deficiency Increased Blood Flow
Recovery and Capillary Density in Ischemic
Limb
Wild-typemice andTlr9−/−micewere subjected to femoral artery
ligation, and serial blood flow measurements were performed by
laser Doppler imaging. Tlr9−/− mice showed better blood flow
recovery than wild-type mice (Figure 2A). To clarify the role
of TLR9 in the process of blood flow recovery, we examined
capillary density in the ischemic limb by histological analysis.
The results of CD31 staining showed that capillary density per
square meter or per muscle fiber in the ischemic limb in Tlr9−/−
mice was higher than that in wild-type mice at 14 days after
ligation (Figure 2B). We also found that Tlr9−/− mice showed
reduced infiltration of macrophages, one of the key players
in the development of inflammation in the ischemic limb at
14 days after surgery, compared with wild-typemice (Figure 2C).
TLR9 Deficiency Reduced Inflammatory
Response in Ischemic Limb
We examined the effect of TLR9 deficiency on the inflammatory
process in the ischemic limb. The results of qPCR demonstrated
that Tlr9−/− mice had reduced expression of TNF-α and F4/80,
a macrophage marker, in the ischemic limb at 3 days after
surgery compared with wild-type mice (Figure 3A). The results
of western blotting confirmed reduced expression of TNF-α in
Tlr9−/− mice at the protein level (Figure 3B). In addition, the
results of western blotting using ischemic limbs showed that
TLR9 deficiency significantly suppressed the degradation of IκBα
compared with wild-type mice, indicating reduced activation of
NF-κB signaling, one of the regulator TNF-α expression, in the
ischemic limb in Tlr9−/− mice (Figure 3C).
Activation of TLR9 Promoted Expression of
TNF-α in Macrophages
Inflammation associated with macrophage activation plays a
pivotal role in blood flow recovery in the ischemic limb.
Therefore, we examined the effect of TLR9 activation in
macrophages. The results of in vitro experiments using peritoneal
macrophages demonstrated that TLR9 activation by ODN1826,
a synthetic oligonucleotide which activates TLR9, promoted
the expression of TNF-α in wild-type macrophages, but not
in Tlr9−/− macrophages (Figure 4A). We further stimulated
these macrophages with plasma obtained from mice which
received femoral artery ligation or sham-operation. Wild-type
macrophages increased TNF-α expression in the presence of
plasma from mice with ischemic muscle compared with that
from sham-operated mice, however, Tlr9−/− macrophages did
not show this response (Figure 4B). The ligation of TLR9 agonist
to wild-typemacrophages significantly activated NF-κB signaling
as determined by the degradation of IκBα, however, this response
was not observed in Tlr9−/− macrophages (Figure 4C).
TLR9-Mediated Macrophage Activation
Attenuated Cell Viability of Endothelial
Cells
To investigate the effect of TLR9-mediated macrophage
activation on endothelial cell, we treated HUVEC with
the CM obtained from wild-type macrophages or Tlr9−/−
macrophages treated with ODN1826. CM obtained from
wild-type macrophage treated with a TLR9 agonist significantly
reduced the viability of HUVEC determined by MTS assay,
although CM from Tlr9−/− macrophage did not have any
effect (Figure 5A). HUVEC treated with TNF-α also showed
attenuated cell viability (Figure 5B). These results suggest
that TNF-α, produced by macrophages via TLR9 activation,
accelerated cell death of endothelial cells, leading to the
suppression of blood flow recovery in ischemic limb.
DISCUSSION
In this study, we demonstrated that femoral artery ligation
increased TLR9 expression in the ischemic limb and circulating
Frontiers in Cardiovascular Medicine | www.frontiersin.org 4 October 2018 | Volume 5 | Article 144
Nishimoto et al. TLR9 and Blood Flow Recovery
FIGURE 2 | TLR9 deficiency increased blood flow recovery and reduced macrophage infiltration in ischemic limb. (A) Wild-type mice and Tlr9−/− mice were
subjected to hind-limb ligation surgery, and serial blood flow in the ischemic limb was monitored. In laser Doppler perfusion images, blue color represents lower
perfusion and red color represents higher reperfusion. The ratio of flow (ischemic limb/non-ischemic limb) was quantitated. Tlr9−/− mice showed better blood flow
recovery compared with wild-type mice (N = 17, per group). (B) Capillary density in gastrocnemius muscle was determined by immunohistochemical staining.
Representative images of CD31 staining (red; CD31 positive) are shown. Capillary density was higher in Tlr9−/− mice compared with wild-type mice (N = 9, per
group). Bar; 100µm. (C) Infiltration of macrophages into the ischemic limb was examined by immunohistochemistry. Tlr9−/− mice showed reduced macrophage
infiltration as determined by Mac3 staining at 14 days after surgery compared with wild-type mice. (N = 9, per group). Bar; 100µm. Insets are larger magnification
(Bar; 50µm). *P < 0.05 and **P < 0.01. All values are mean ± SEM.
cfDNA, an endogenous ligand for TLR9, in plasma. The
results of in vivo experiment demonstrated that genetic deletion
of TLR9 increased capillary density in ischemic muscle and
promoted blood flow recovery. Genetic deletion of TLR9
attenuated inflammation as determined by TNF-α expression
in the ischemic limb. The results of in vitro experiments
using macrophages and HUVEC indicated that TLR9-mediated
macrophage activation attenuated cell viability of HUVEC.
These results suggest that TLR9 activation caused by cfDNA
released from ischemic muscle promotes inflammation, leading
to deterioration of blood flow recovery.
Accumulating evidence has suggested the involvement of
the innate immune system in the pathophysiology of various
diseases (18–21). In this process, host-derived internal ligands
initiate and promote sterile chronic inflammation. Ischemic or
damaged tissue releases various molecules, such as fatty acids,
nuclear proteins, and nucleic acids, which can activate pattern
recognition receptors including TLRs as endogenous ligands
(22). cfDNA is one of these internal ligands which activates TLR9.
Previous studies have reported the association of circulating
cfDNA level with the pathophysiology and/or severity of chronic
inflammatory diseases, including severe cardiovascular diseases,
and suggested the role of cfDNA as a biomarker of several chronic
inflammatory diseases (16, 23, 24). Our results showed that hind-
limb ischemia increased TLR9 expression in ischemic muscle
and the circulating level of cfDNA, suggesting that cfDNA-TLR9
signaling participates in the process of blood flow recovery.
A number of previous studies reported the contribution of
TLR signaling to neovascularization or blood flow recovery after
ischemia. However, its roles are still under debate. TLR4 is one
of the most studied TLRs from the perspective of blood flow
recovery after ischemia. Several studies reported that the absence
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FIGURE 3 | TLR9 deficiency reduced inflammation in ischemic limb. (A) The result of qPCR analysis demonstrated that the expression of TNF-α and F4/80 in ischemic
limb at 3 days after surgery was lower in Tlr9−/− mice than in wild-type mice (N = 6-7, per group). (B) Protein level of TNF-α in ischemic muscle in Tlr9−/− mice was
lower than that in wild-type mice (N = 4-6, per group). (C) The degradation of IκBα in the ischemic limb was significantly suppressed in Tlr9−/− mice compared with
wild-type mice, suggesting suppression of NF-κB signaling in Tlr9−/− mice (N = 4-6, per group). *P < 0.05 and **P < 0.01. All values are mean ± SEM.
of TLR4 attenuates collateral formation and tissue perfusion after
arterial occlusion (10, 25). In addition, lipopolysaccharide, an
exogenous TLR4 ligand, stimulates collateral artery formation
after arterial occlusion (11, 26). These studies indicated
that TLR4-mediated inflammation resulted in proliferation of
collateral arteries and improvement of blood flow recovery.
On the contrary, recent studies demonstrated that activation of
TLR4 impairs blood flow recovery after ischemia. Suppression of
TLR4-mediated inflammation is associated with muscle recovery
and rapid blood flow recovery in TLR4-deficient mice (11, 27).
Also, lack of CD180, a specific inhibitor of the TLR4-mediated
inflammatory response, accelerated inflammation and retarded
blood flow recovery after ischemia (6, 28). These studies indicated
that unrestrained inflammation impaired blood flow recovery.
Therefore, adequate inflammation is important for promoting
blood flow recovery in ischemic tissues.
Few studies have reported the role of TLR9 signaling in
blood flow recovery in the ischemic limb, although several
previous studies examined its role in angiogenesis using different
models. One study reported that TLR9 signaling stimulated
wound healing by enhancing blood flow (29). On the other
hand, other studies demonstrated that TLR9 activation reduced
vessel sprouting from aortic rings and hemangiogenesis and
lymphangiogenesis in a suture-induced corneal angiogenesis
model (30). Also, another in vitro study reported that TLR9
activation with a lower concentration of ODN1826, a TLR9
agonist, stimulated angiogenesis, although activation with a
higher concentration of ODN1826 impaired angiogenesis (31).
This study suggested dual roles of ODN1826 in angiogenesis.
This discrepancy might have been due to the difference in
models used in these studies; however, adequate control of TLR9
activation seems to be essential for angiogenesis.
In our present study, we demonstrated that genetic deletion
of TLR9 reduced TNF-α expression in the ischemic limb. We
also found that TLR9 activation by ODN1826 promoted TNF-α
expression in macrophages, one of the key players in blood flow
recovery in the ischemic limb. Furthermore, plasma obtained
from mice with ischemic muscle increased TNF-α expression in
wild-type macrophages but not in Tlr9−/− macrophages. These
results suggested that TLR9 activation by endogenous ligands
released from ischemic muscle promotes TNF-α expression in
macrophages, regulating blood flow recovery in ischemic limb.
In this study, genetic deletion of TLR9 reduced the degradation
of IκBα in ischemic muscle, suggesting suppression of NF-κB
signaling. Previous studies have reported that TLR signaling
pathways activate NF-κB, which regulates the expression of
inflammatory cytokines including TNF-α (32, 33). As well as
other TLRs, TLR9 signaling also activates this pathway (16). In
fact, we demonstrated that the ligation of TLR9 agonist activates
NF-κB signaling in wild-type macrophages as determined by the
degradation of IκBα, but not in by Tlr9−/− macrophages in this
study. Our results suggested the link between TLR9 and NF-κB,
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FIGURE 4 | TLR9 activation promoted TNF-α expression in macrophages. (A) Activation of TLR9 by ODN1826 (0.1-1.0µM) for 4 h promoted the expression of TNF-α
in wild-type macrophages but not in Tlr9−/− macrophages (N = 4, per group). (B) Wild-type or Tlr9−/− macrophages were treated with plasma obtained from
wild-type mice which received femoral ligation or sham operation for 4 h. Plasma from mice with ischemic muscle increased TNF-α expression in wild-type
macrophages compared with that from sham-operated mice, however, plasma from mice with ischemic muscle did not show this response in Tlr9−/− macrophages
(N = 4-6, per group). (C) ODN1826 promoted degradation of IκBα in wild-type macrophages in time dependent manner, suggesting the activation of NF-κB signaling.
In Tlr9−/− macrophages, this response was not observed. *P < 0.05 and ***P < 0.001. All values are mean ± SEM.
at least partially, although further studies are needed to elucidate
precise signaling in ischemic muscle. Previous studies reported
that TNF-α has two contradictory functions on endothelial cells
(34–36). This contradiction has been partially explained by tissue
TNF-α concentration (34). That is, a low TNF-α concentration
promotes, but a high TNF-α concentration inhibits angiogenesis.
Previous in vitro studies, a higher concentration of TNF-α
reduced cell viability of endothelial cells (34, 36). The result of
our experiment is consistent with these studies. Furthermore, in
this study, CM obtained from wild-type macrophages activated
by a TLR9 agonist attenuated cell viability of HUVEC, although
CM from Tlr9−/− macrophage did not have any effect. These
results suggest that suppression of TNF-α expression in TLR9-
deficient macrophages is associated with higher capillary density
and better blood flow recovery through inhibition of endothelial
cell death. Combined with the results of previous studies, the
results of our study suggest that well-controlled activation of
TLR9 is important for blood flow recovery in the ischemic
limb by regulating TNF-α expression. Several clinical studies
have demonstrated elevated plasma level of TNF-α in patients
with PAD (37, 38). Further studies are required to determine
the role of cfDNA-TLR9 signaling in inflammation and blood
flow recovery in ischemic tissues, which might provide a novel
therapeutic strategy for PAD.
There are several limitations in this study. The time point we
examined blood flow, capillary density, and inflammatory status
in the ischemic limb was limited. In vitro experiments were also
performed at limited time point. Other cell types or signaling
pathways might also have roles in different time points. Second,
we focused on pro-inflammatory activation of macrophages
via TLR9, however, we did not perform macrophage-specific
investigation in our in vivo studies. Therefore, other cell-types
might also contribute to the results. Last, the results of our in
vivo study suggested that TLR9-deletion promotes blood flow
recovery in ischemic muscle. However, functional analysis was
not performed in this study.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 October 2018 | Volume 5 | Article 144
Nishimoto et al. TLR9 and Blood Flow Recovery
FIGURE 5 | TLR9-induced macrophage activation accelerated cell death of HUVEC. (A) HUVEC were treated with the CM obtained from wild-type or Tlr9−/−
macrophages treated with ODN1826 or control-ODN1826. At 72 h after treatment, the viability of HUVEC determined by MTS assay was significantly reduced by CM
obtained from wild-type macrophage activated by ODN1826, although the viability of HUVEC was not affected by CM obtained from Tlr9−/− macrophage (N = 5, per
group). (B) Stimulation with TNF-α for 24 h decreased cell viability in HUVEC as determined by MTS assay (N = 4-6, per group). *P < 0.05 and **P < 0.01. All values
are mean ± SEM.
Inflammation regulates blood flow recovery in ischemic
tissues. The results of our present study suggested that TLR9-
deletion attenuates inflammatory responses and promotes blood
flow recovery in ischemic muscle. These results indicate that
strict control of inflammation and appropriate expression
of TNF-α through TLR9 signaling in ischemic tissues are
critical for blood flow recovery. Regulation of cfDNA-TLR9
signaling could be a potential therapeutic strategy for regulation
and acceleration of blood flow recovery in ischemic limb
injury.
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